HEPARIN-INDUCED THROMBOCYTOPENIA IN HEMODIALYSIS. CASE REPORT

As a rule, heparin-induced thrombocytopenia is a rather rare complication and it is a result of orthopedic or cardiac surgery, on average this disease occurs in 5% of patients receiving unfractionated heparin. This type of heparin is a powerful anticoagulant and is widely used to prevent arterial and venous thrombosis, despite the availability of no less effective alternative agents (low molecular weight heparin, direct thrombin inhibitors). It should also be noted the difficulty of diagnosing heparin-induced thrombocytopenia in the early stages due to the lack of appropriate medical equipment, which in turn is a cause of difficulties in the treatment and further prognosis for the patient. The probability of this complication depends on the molecular weight of the administered heparin (28, 34, 58) and rarely occurs in using low-molecular-weight heparin. It should be noted that thrombocytopenia is a potential complication of heparin therapy. There are two forms of heparin-induced thrombocytopenia. Heparin-induced type I thrombocytopenia is characterized by a moderate decrease in the number of platelets that occurs within the first 2-4 days after the onset of heparin. The number of platelets often returns to normal without stopping treatment by heparin.